Business Wire

Mobidiag Announces Joint Venture with Autobio Diagnostics and €10m Equity Investment

Jaa

Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of antimicrobial resistance, today announces that it has entered into a joint venture (‘JV’) agreement with Autobio Diagnostics (‘Autobio’), one of the leading clinical diagnostics companies in China, to commercialise the Novodiag® platform in China. In addition, Mobidiag announces that it has secured a separate €10m equity investment from Autobio. Lynx Financial (HK) Ltd, served as the exclusive financial advisor to Mobidiag in this transaction.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181217005272/en/

Mobidiag and Autobio will jointly invest €12.3m to establish a joint venture company in China. Autobio will invest €8m in cash to hold 65%, and Mobidiag will invest €4.3m to hold 35%.

Mobidiag will grant to the JV an exclusive license for human infectious disease assays (except for sepsis) for China. Initial activities of the JV will include the registration of the Novodiag® platform and three assays for the rapid detection of respiratory and gastroenteric infections and meningitis with the National Medical Products Administration (NMPA, former CFDA). The JV will also finance the establishment of local facilities in China to manufacture some Novodiag® components and disposables.

Proceeds from the €10m equity investment will be used by Mobidiag to continue growing its product portfolio, accelerate the development of further assays for the Novodiag® system and enhance its manufacturing capabilities, as well as continuing to facilitate Mobidiag’s commercial expansion.

The Novodiag® platform is an innovative molecular diagnostics solution allowing fully automated detection of infectious diseases, including antibiotic resistances. The platform combines real-time PCR and microarray technologies, to allow direct analysis of samples placed in a disposable cartridge. It also allows for comprehensive screening of multiple or single pathogens within approximately one hour, allowing clinicians to be better informed when making time-critical decisions, helping to deliver early treatments and avoid the spread of infection.

Tuomas Tenkanen, CEO of Mobidiag, said “We are excited to enter into this new Joint Venture with Autobio Diagnostics, a leader in IVD field in China. We are confident that their unparalleled access to the rapidly growing Chinese market combined with Mobidiag’s deep expertise in molecular diagnostics will result in a successful partnership that will bring syndromic diagnostic panels to China at an affordable price.

“The €10m equity investment strengthens our cash balance and will allow us to advance our wider strategy to grow sales internationally and launch more innovative and affordable molecular solutions to advance the diagnosis of infectious diseases and antibiotic resistances.”

Yongjun Miao, Chairman of Autobio said “In China, due to a lack of rapid, accurate and low cost diagnosis of pathogens, the timely and effective treatment of infectious diseases is limited and the misuse of antibiotics is not uncommon. Mobidiag’s Novodiag ® system is low cost, easy to operate, multi-target, and has a wide application and great market prospects. The cost advantages of setting up Joint Venture in China will further enhance the competitive force of the Novodiag ® system. Both Mobidiag’s and Autobio’s teams share the same vision for the Joint Venture, and already have a common culture, and we are excited by the prospects for the future.”

Donald Xu, Managing Partner of Lynx Financial, commented: “This deal epitomizes the current trend in cross-border transactions in the healthcare sectors between China and western countries. The strategy of combining investment with joint venture, will be the playbook for many upcoming and innovative companies to catapult their regulatory and commercialization process, and to compete against the entrenched MNCs, not only in China market, but also the rest of the world.”

Notes to editors

About Mobidiag Ltd

Mobidiag is a commercial stage, fast growing molecular diagnostics company whose affordable, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of antimicrobial resistance (AMR) by rapid detection of pathogens and their potential resistance to antibiotics. Through its Amplidiag® and Novodiag® solutions, Mobidiag offers a comprehensive range of fast, reliable and cost-effective molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.

Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com

About Autobio Diagnostics Co, Ltd

Founded in 1998, Autobio has become one of the leading clinical diagnostics companies in China. Autobio specializes in research & development, production, marketing and service of clinical diagnostic products, including immunoassay, microbiology and biochemical products. Autobio provides comprehensive solutions for medical laboratories.

About Lynx Financial

Lynx Financial is a leading boutique Investment bank focusing on Life Sciences and Healthcare sectors. With offices in both China and U.S., Lynx Financial specializes in cross-border transactions involving private placement, M&A, joint venture and licensing.

Contact information

Mobidiag
Dorothee Allard, Marketing Communications Manager
+33 1 55 25 17 13
marketing@mobidiag.com

Lynx Financial (Financial Advisor in China)
Flora Gao, Senior Vice President
1501 Century Ave.
GuoHua Life Financial Center, Suite 1001
Shanghai, China 200122
lynx@lynx-financial.com

WG Partners (Financial advisor to the company outside the China region)
Andrew Craig, Partner
+44 203 705 9320
andrew@wgpartners.co.uk

Consilium Strategic Communications
Chris Gardner, Matthew Neal, Chris Welsh
T: +44 (0)203 709 5700
mobidiag@consilium-comms.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Axonics® Announces U.S. Food & Drug Administration Approves Use of Full-Body MRI for Pivotal Study Patients18.6.2019 13:00:00 EESTTiedote

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable sacral neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the U.S. Food & Drug Administration (“FDA”) approved the use of full-body magnetic resonance imaging (“MRI”) using 1.5 Tesla MRI scanners for clinical study patients implanted with the Axonics System. The approval was a result of a supplement filed by Axonics with the FDA under the Investigational Device Exemption (“IDE”) regarding the Company’s ARTISAN-SNM 129-patient pivotal clinical study. The FDA concluded that Axonics provided sufficient data to support full-body MRIs. Raymond W. Cohen, CEO of Axonics, commented, “Allowing full-body MRI scans for our clinical study patients means that none will have to undergo an explant of their neurostimulator device should they require an MRI. We view this as a very positive step by the FD

Norsk Titanium Receives Airbus Contract for Qualification and Production18.6.2019 13:00:00 EESTTiedote

Officials with Norsk Titanium (Norsk) announce today a contract award from Airbus for the Qualification and Serial Production of the first parts to be manufactured utilizing wire-based Direct Energy Deposition (DED) additive manufacturing technology. “We have worked closely with Airbus over several years to demonstrate the technological maturity and the industrial readiness of our Rapid Plasma Deposition™ (RPD™) process,” said Norsk President and CEO Michael Canario. “This contract award is structured to enable long-term, serial production immediately following qualification. Our Plattsburgh, New York facility, with the assistance of Airbus technical leadership, has been preparing for this moment and is eager to demonstrate a 21st century advanced additive manufacturing capability.” This qualification of Airbus parts will demonstrate the suitability of the DED additive manufacturing process for aircraft structural parts. It will formalize the process by which individual parts are produ

Innovusion Announces Its High-Resolution Image-Grade LiDAR System “Cheetah”, Enabling the Safest Performance in the Vehicle Mobility Industry18.6.2019 12:00:00 EESTTiedote

Innovusion Inc., the worldwide leader in the design and development of innovative hybrid Solid State LiDAR systems for vehicle safety applications, has announced the availability of its Cheetah system. Based on its innovative rotating polygon optical architecture, Innovusion has melded together proprietary detector electronics, advanced optics and sophisticated software algorithms to offer a system that has no equal in the long-distance, high-resolution LiDAR vehicle mobility system industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190618005066/en/ Innovusion's Cheetah long-distance LiDAR System...the safest in the mobility safety industry (Graphic: Business Wire) Smart architecture, streamlined optics design, and integrated optical paths result in rapid manufacturing, scalability into automotive production, and lower cost. The ability to provide a detection range of 200 meters on objects with 10% reflectivity and cle

You Bank the Digital Asset Banking Platform Presents at UNCHAIN 2019 in Berlin18.6.2019 11:25:00 EESTTiedote

The Blockchain Conference UNCHAIN 2019 was held in Berlin, Germany, from June 14 to 15, 2019. You Bank, a digital asset banking platform, attended and delivered a speech at the conference. You Bank has henceforth made a brilliant appearance in the European market and officially opened the prelude of the global layout! You Bank’s Digital Asset Banking Platform, the Federal Reserve of the Digital World You Bank, a world-class multinational blockchain financial service platform, is a well-deserved global leader in the field of digital asset management. Headquartered in Singapore, You Bank was founded by the Richmond family, one of the nine Jewish families known as the "Rothschild" family in the digital world. You Bank Global CEO Daniel attended and delivered a speech at the conference. He introduced that the original intention of You Bank was to establish a digital bank which could operate world-widely in the digital economy era. You Bank will cover digital asset management, digital asset

Norsk Titanium Marks Milestone in Additive Manufacturing18.6.2019 11:00:00 EESTTiedote

Officials with the University of Notre Dame Turbomachinery Laboratory (NDTL), Norsk Titanium (Norsk), Pratt & Whitney and TURBOCAM International announce the continuation of testing of an additively manufactured integrally bladed rotor (IBR). Building on initial testing completed in 2018, this next phase of testing examines the dynamic properties of the IBR. Manufactured using Norsk’s revolutionary Rapid Plasma Deposition™ (RPD™) process, the IBR was inspected to the same quality specifications used in Pratt & Whitney’s current turbomachinery components. The tests are being conducted at NDTL’s world-class turbomachinery test facility in South Bend, Indiana. After completion of the initial testing, where the IBR met 100% of all design, speed and pressure ratio test points, the current test program looks at low and high cycle fatigue characteristics of the IBR. Testing will include multiple acceleration/deceleration cycles and investigate synchronous vibration effects on the additively m

Hansol Paper and Iconex Announce Mutual Decision to Withdraw from Agreement Governing Sale of Schades and R+S to Iconex18.6.2019 11:00:00 EESTTiedote

Iconex and Hansol Paper announced today that the companies are withdrawing from their definitive agreement signed November 2, 2018, under which Iconex would have acquired Schades and R+S from Hansol Paper. This decision, reached by mutual agreement between the parties, is due to the ruling of The United Kingdom’s Competition and Markets Authority (CMA) to move the approval process for this transaction to Phase 2. This allows the UK CMA an additional six months to reach a decision, which was deemed to be too long of a delay by both parties. The parties believe that the proposed transaction met the relevant legal criteria for approval in the UK, and that it was in the best interests of our customers, employees and the marketplace in the United Kingdom and beyond. This UK CMA decision was unexpected by both parties given that the European Commission cleared the deal earlier this spring. Like elsewhere in Europe, the UK market is highly competitive with a significant number of players. “Th

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme